Suppr超能文献

Sec61 复合物抑制剂和新型高通量筛选策略靶向蛋白易位途径。

Inhibitors of the Sec61 Complex and Novel High Throughput Screening Strategies to Target the Protein Translocation Pathway.

机构信息

KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.

Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Str. 10, 13125 Berlin, Germany.

出版信息

Int J Mol Sci. 2021 Nov 5;22(21):12007. doi: 10.3390/ijms222112007.

Abstract

Proteins targeted to the secretory pathway start their intracellular journey by being transported across biological membranes such as the endoplasmic reticulum (ER). A central component in this protein translocation process across the ER is the Sec61 translocon complex, which is only intracellularly expressed and does not have any enzymatic activity. In addition, Sec61 translocon complexes are difficult to purify and to reconstitute. Screening for small molecule inhibitors impairing its function has thus been notoriously difficult. However, such translocation inhibitors may not only be valuable tools for cell biology, but may also represent novel anticancer drugs, given that cancer cells heavily depend on efficient protein translocation into the ER to support their fast growth. In this review, different inhibitors of protein translocation will be discussed, and their specific mode of action will be compared. In addition, recently published screening strategies for small molecule inhibitors targeting the whole SRP-Sec61 targeting/translocation pathway will be summarized. Of note, slightly modified assays may be used in the future to screen for substances affecting SecYEG, the bacterial ortholog of the Sec61 complex, in order to identify novel antibiotic drugs.

摘要

靶向分泌途径的蛋白质通过穿过内质网 (ER) 等生物膜开始其细胞内旅程。在这个穿过 ER 的蛋白质易位过程中,Sec61 转运蛋白复合物是一个核心组成部分,它仅在细胞内表达,没有任何酶活性。此外,Sec61 转运蛋白复合物难以纯化和重组。因此,筛选能够抑制其功能的小分子抑制剂一直是一项艰巨的任务。然而,鉴于癌细胞严重依赖于高效的蛋白质易位进入 ER 以支持其快速生长,这种易位抑制剂不仅可能是细胞生物学的有价值工具,而且可能代表新型抗癌药物。在这篇综述中,将讨论不同的蛋白质易位抑制剂,并比较它们的特定作用模式。此外,还将总结最近发表的针对整个 SRP-Sec61 靶向/易位途径的小分子抑制剂的筛选策略。值得注意的是,未来可能会使用略微修改的测定方法来筛选影响 SecYEG(Sec61 复合物的细菌同源物)的物质,以识别新型抗生素药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8585047/e4840fd71a83/ijms-22-12007-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验